Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum

Brian Decker, Kalisha D. O'Neill, Mary A. Chambers, James E. Slaven, Zhangsheng Yu, David R. Jones, Sharon Moe

Research output: Contribution to journalArticle

Abstract

There is a paucity of studies evaluating the change in liver metabolism in subjects receiving hemodialysis. The purpose of this study was to compare the effect of uremic toxins on hepatic cytochrome P450 (CYP)3A4 and CYP2D6 metabolism before and after a 4-hour hemodialysis session. Midazolam and dextromethorphan were incubated with uremic serum collected from subjects before and after the 4-hour hemodialysis session. Analysis and quantification of the 1′-OH-midazolam and 4-OH-midazolam and dextrorphan metabolites were performed by high-pressure liquid chromatography/mass spectrometry. Statistical analysis using the Student's t-test (paired) was used to compare the amount of metabolite formed. The mean amount of 1′-OH-midazolam, 4-OH-midazolam, and dextrorphan metabolites formed before and after hemodialysis did not significantly differ. There was no significant difference in CYP3A4 and CYP2D6 metabolic activity in uremic serum before and after hemodialysis.

Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalClinical Pharmacology: Advances and Applications
Volume5
DOIs
StatePublished - Dec 10 2013

Fingerprint

Cytochrome P-450 CYP3A
Cytochrome P-450 CYP2D6
Midazolam
Renal Dialysis
Dextrorphan
Liver
Serum
Dextromethorphan
Mass Spectrometry
High Pressure Liquid Chromatography
In Vitro Techniques
Students
hydroxide ion

Keywords

  • CYP2D6
  • CYP3A4
  • Hemodialysis
  • Metabolism
  • Uremia

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum. / Decker, Brian; O'Neill, Kalisha D.; Chambers, Mary A.; Slaven, James E.; Yu, Zhangsheng; Jones, David R.; Moe, Sharon.

In: Clinical Pharmacology: Advances and Applications, Vol. 5, 10.12.2013, p. 193-199.

Research output: Contribution to journalArticle

@article{78eab76ece8143209b679c7d514e93bf,
title = "Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum",
abstract = "There is a paucity of studies evaluating the change in liver metabolism in subjects receiving hemodialysis. The purpose of this study was to compare the effect of uremic toxins on hepatic cytochrome P450 (CYP)3A4 and CYP2D6 metabolism before and after a 4-hour hemodialysis session. Midazolam and dextromethorphan were incubated with uremic serum collected from subjects before and after the 4-hour hemodialysis session. Analysis and quantification of the 1′-OH-midazolam and 4-OH-midazolam and dextrorphan metabolites were performed by high-pressure liquid chromatography/mass spectrometry. Statistical analysis using the Student's t-test (paired) was used to compare the amount of metabolite formed. The mean amount of 1′-OH-midazolam, 4-OH-midazolam, and dextrorphan metabolites formed before and after hemodialysis did not significantly differ. There was no significant difference in CYP3A4 and CYP2D6 metabolic activity in uremic serum before and after hemodialysis.",
keywords = "CYP2D6, CYP3A4, Hemodialysis, Metabolism, Uremia",
author = "Brian Decker and O'Neill, {Kalisha D.} and Chambers, {Mary A.} and Slaven, {James E.} and Zhangsheng Yu and Jones, {David R.} and Sharon Moe",
year = "2013",
month = "12",
day = "10",
doi = "10.2147/CPAA.S54381",
language = "English",
volume = "5",
pages = "193--199",
journal = "Clinical Pharmacology: Advances and Applications",
issn = "1179-1438",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum

AU - Decker, Brian

AU - O'Neill, Kalisha D.

AU - Chambers, Mary A.

AU - Slaven, James E.

AU - Yu, Zhangsheng

AU - Jones, David R.

AU - Moe, Sharon

PY - 2013/12/10

Y1 - 2013/12/10

N2 - There is a paucity of studies evaluating the change in liver metabolism in subjects receiving hemodialysis. The purpose of this study was to compare the effect of uremic toxins on hepatic cytochrome P450 (CYP)3A4 and CYP2D6 metabolism before and after a 4-hour hemodialysis session. Midazolam and dextromethorphan were incubated with uremic serum collected from subjects before and after the 4-hour hemodialysis session. Analysis and quantification of the 1′-OH-midazolam and 4-OH-midazolam and dextrorphan metabolites were performed by high-pressure liquid chromatography/mass spectrometry. Statistical analysis using the Student's t-test (paired) was used to compare the amount of metabolite formed. The mean amount of 1′-OH-midazolam, 4-OH-midazolam, and dextrorphan metabolites formed before and after hemodialysis did not significantly differ. There was no significant difference in CYP3A4 and CYP2D6 metabolic activity in uremic serum before and after hemodialysis.

AB - There is a paucity of studies evaluating the change in liver metabolism in subjects receiving hemodialysis. The purpose of this study was to compare the effect of uremic toxins on hepatic cytochrome P450 (CYP)3A4 and CYP2D6 metabolism before and after a 4-hour hemodialysis session. Midazolam and dextromethorphan were incubated with uremic serum collected from subjects before and after the 4-hour hemodialysis session. Analysis and quantification of the 1′-OH-midazolam and 4-OH-midazolam and dextrorphan metabolites were performed by high-pressure liquid chromatography/mass spectrometry. Statistical analysis using the Student's t-test (paired) was used to compare the amount of metabolite formed. The mean amount of 1′-OH-midazolam, 4-OH-midazolam, and dextrorphan metabolites formed before and after hemodialysis did not significantly differ. There was no significant difference in CYP3A4 and CYP2D6 metabolic activity in uremic serum before and after hemodialysis.

KW - CYP2D6

KW - CYP3A4

KW - Hemodialysis

KW - Metabolism

KW - Uremia

UR - http://www.scopus.com/inward/record.url?scp=84890406550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890406550&partnerID=8YFLogxK

U2 - 10.2147/CPAA.S54381

DO - 10.2147/CPAA.S54381

M3 - Article

AN - SCOPUS:84890406550

VL - 5

SP - 193

EP - 199

JO - Clinical Pharmacology: Advances and Applications

JF - Clinical Pharmacology: Advances and Applications

SN - 1179-1438

ER -